Innocan Pharma Corporation has announced that a divisional application for its Chinese (CN) liposome-based CBD technology patent was filed.

Following the recently granted patent in India for a prolonged-release pharmaceutical formulation using liposomes to encapsulate CBD, Innocan is actively advancing its efforts to strengthen intellectual property protection across additional Asian markets.

China, the second-largest pharmaceutical market in the world, was valued at USD 163 billion in medicine spending in 2023 (IQVIA). The filing of this divisional application in China reflects the expertise and commitment of the Innocan team and represents a strategic step in aligning the company's intellectual property portfolio with its long-term global business objectives.

This application protects Innocan's synthetic CBD-loaded Liposome Injection Platform (LPT-CBD), developed jointly in collaboration with Professor Chezy Barenholz and Dr. Ahuva Cern from the Hebrew University in Jerusalem. The liposomal drug delivery platform allows for prolonged exposure and maximizes the bioavailability and therapeutic effects of CBD.

Iris Bincovich, Chief Executive Officer of Innocan said, “Establishing a comprehensive global patent strategy enables us to effectively support the company's broader business objectives in the global pharmaceutical market—particularly within the rapidly growing Asian region.”

Dr. Eyal Kalo, Vice President of R&D, commented, “LPT-CBD demonstrates sustained pharmacokinetics and has shown efficacy across multiple animal models of chronic pain. We are extremely proud of our team's efforts in advancing the innovation behind LPT-CBD, enabling us to secure broad international intellectual property protection.”